Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aloxi Payment Cut By One-Third Under Medicare ASP Rule

Executive Summary

MGI's anti-emetic Aloxi is among the products that will see the steepest payment cuts when the Centers for Medicare & Medicaid Services implements average sales price-based reimbursement for drugs covered by Medicare Part B in 2005

You may also be interested in...



Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP

MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class

Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP

MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class

Average Sales Prices Expected To Increase 3.4% From Proposed Rule

The Centers for Medicare & Medicaid Services expects that first quarter 2005 reimbursement rates for Medicare Part B drugs will reflect an increase of about 3.4% from those published in its proposed rule

Related Content

Topics

UsernamePublicRestriction

Register

PS044410

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel